Recruiting
Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Drug: letrozole, Drug: tamoxifen citrate
Phase: Phase III
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Drug: letrozole, Drug: tamoxifen citrate
Phase: Phase III
Recruiting
Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Drug: ixabepilone, Drug: paclitaxel, Drug: paclitaxel albumin-stabilized nanoparticle formulation
Phase: Phase III
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Drug: ixabepilone, Drug: paclitaxel, Drug: paclitaxel albumin-stabilized nanoparticle formulation
Phase: Phase III
Recruiting
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Everolimus, Drug: Placebo
Phase: Phase III
Conditions: Breast Cancer
Interventions: Drug: Everolimus, Drug: Placebo
Phase: Phase III
Recruiting
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: capecitabine [Xeloda]
Phase: Phase III
Conditions: Breast Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: capecitabine [Xeloda]
Phase: Phase III
Recruiting
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab, Drug: vinorelbine + trastuzumab
Phase: Phase III
Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab, Drug: vinorelbine + trastuzumab
Phase: Phase III
Recruiting
Bevacizumab and Paclitaxel or Bevacizumab, Cyclophosphamide, and Capecitabine as First-Line Therapy in Treating Women With Locally Advanced, Recurrent, or Metastatic Breast Cancer
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Drug: capecitabine, Drug: cyclophosphamide, Drug: paclitaxel, Other: questionnaire administration, Procedure: quality-of-life assessment
Phase: Phase III
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Drug: capecitabine, Drug: cyclophosphamide, Drug: paclitaxel, Other: questionnaire administration, Procedure: quality-of-life assessment
Phase: Phase III
Recruiting
A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Taxane, Avastin, Drug: Taxane, Avastin, Xeloda
Phase: Phase III
Conditions: Breast Cancer
Interventions: Drug: Taxane, Avastin, Drug: Taxane, Avastin, Xeloda
Phase: Phase III
Recruiting
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine, Drug: Placebo / Capecitabine
Phase: Phase III
Conditions: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine, Drug: Placebo / Capecitabine
Phase: Phase III
Recruiting
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
Conditions: Breast Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: Chemotherapy
Phase: Phase III
Conditions: Breast Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: Chemotherapy
Phase: Phase III
Recruiting
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
Conditions: First Line Metastatic Breast Cancer
Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Drug: Exemestane
Phase: Phase III
Conditions: First Line Metastatic Breast Cancer
Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Drug: Exemestane
Phase: Phase III
Recruiting
Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: docetaxel and epirubicin, Drug: docetaxel and epirubicin plus endostatin
Phase: Phase III
Conditions: Breast Cancer
Interventions: Drug: docetaxel and epirubicin, Drug: docetaxel and epirubicin plus endostatin
Phase: Phase III
Recruiting
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Conditions: Breast Cancer
Interventions: Drug: Trastuzumab, Drug: Bevacizumab, Drug: Docetaxel
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Trastuzumab, Drug: Bevacizumab, Drug: Docetaxel
Phase: Phase II
Recruiting
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Abraxane, Drug: Bevacizumab, Drug: Carboplatin
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Abraxane, Drug: Bevacizumab, Drug: Carboplatin
Phase: Phase II
Recruiting
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Conditions: Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate, Drug: paclitaxel, Drug: doxorubicin hydrochloride, Drug: cyclophosphamide, Biological: filgrastim, Procedure: therapeutic conventional surgery, Other: laboratory biomarker analysis, Other: flow cytometry
Phase: Phase II
Conditions: Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate, Drug: paclitaxel, Drug: doxorubicin hydrochloride, Drug: cyclophosphamide, Biological: filgrastim, Procedure: therapeutic conventional surgery, Other: laboratory biomarker analysis, Other: flow cytometry
Phase: Phase II
Recruiting
Brain Mets - Capecitabine and WBRT
Conditions: Breast Cancer
Interventions: Drug: sunitinib, Drug: capecitabine, Radiation: WBRT
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: sunitinib, Drug: capecitabine, Radiation: WBRT
Phase: Phase II
Recruiting
Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Conditions: Breast Cancer
Interventions: Drug: RAD001, Drug: Fulvestrant
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: RAD001, Drug: Fulvestrant
Phase: Phase II
Recruiting
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer
Interventions: Drug: Doxil, Drug: Carboplatin, Drug: Bevacizumab
Phase: Phase II
Conditions: Metastatic Breast Cancer
Interventions: Drug: Doxil, Drug: Carboplatin, Drug: Bevacizumab
Phase: Phase II
Recruiting
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Drug: carboplatin, Drug: ABI-007l albumin-stabilized nanoparticle formulation
Phase: Phase II
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Drug: carboplatin, Drug: ABI-007l albumin-stabilized nanoparticle formulation
Phase: Phase II
Recruiting
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation, Biological: bevacizumab, Drug: erlotinib hydrochloride, Other: immunohistochemistry staining method, Other: flow cytometry, Other: laboratory biomarker analysis
Phase: Phase II
Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation, Biological: bevacizumab, Drug: erlotinib hydrochloride, Other: immunohistochemistry staining method, Other: flow cytometry, Other: laboratory biomarker analysis
Phase: Phase II
Recruiting
Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Bevacizumab, Drug: Docetaxel, Drug: Gemcitabine
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Bevacizumab, Drug: Docetaxel, Drug: Gemcitabine
Phase: Phase II
Recruiting
A Study of Avastin (Bevacizumab) in Combination With Neoadjuvant Treatment Regimens in Patients With Primary HER2 Negative Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: Placebo, Drug: Standard chemotherapy or endocrine therapy
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: Placebo, Drug: Standard chemotherapy or endocrine therapy
Phase: Phase II
Recruiting
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Conditions: Breast Cancer
Interventions: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Phase: Phase II
Recruiting
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: paclitaxel albumin-stabilized nanoparticle formulation
Phase: Phase II
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: paclitaxel albumin-stabilized nanoparticle formulation
Phase: Phase II
Recruiting
Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Trastuzumab (Herceptin), Drug: Trastuzumab (Herceptin) plus Everolimus
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Trastuzumab (Herceptin), Drug: Trastuzumab (Herceptin) plus Everolimus
Phase: Phase II
Recruiting
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: cisplatin, Drug: everolimus, Drug: paclitaxel, Other: placebo
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: cisplatin, Drug: everolimus, Drug: paclitaxel, Other: placebo
Phase: Phase II
Recruiting
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Conditions: Solid Tumors, Cancer
Interventions: Drug: XL184, Drug: Placebo, Drug: XL184, Drug: XL184
Phase: Phase II
Conditions: Solid Tumors, Cancer
Interventions: Drug: XL184, Drug: Placebo, Drug: XL184, Drug: XL184
Phase: Phase II
Recruiting
A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early
Conditions: Breast Cancer
Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Bevacizumab
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Bevacizumab
Phase: Phase II
Recruiting
Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer
Conditions: Neoplasms
Interventions: Drug: bevacizumab plus docetaxel
Phase: Phase II
Conditions: Neoplasms
Interventions: Drug: bevacizumab plus docetaxel
Phase: Phase II
Recruiting
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Conditions: Carcinoma Breast Stage IV, Breast Cancer, Progressive Breast Cancer
Interventions: Drug: carboplatin, Drug: bevacizumab, Drug: herceptin
Phase: Phase II
Conditions: Carcinoma Breast Stage IV, Breast Cancer, Progressive Breast Cancer
Interventions: Drug: carboplatin, Drug: bevacizumab, Drug: herceptin
Phase: Phase II
Recruiting
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors
Interventions: Drug: Neratinib, Drug: ABT-888, Drug: Standard Therapy, Drug: AMG 386
Phase: Phase II
Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors
Interventions: Drug: Neratinib, Drug: ABT-888, Drug: Standard Therapy, Drug: AMG 386
Phase: Phase II
Recruiting
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
Conditions: Triple Negative Metastatic Breast Cancer
Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Drug: Capecitabine
Phase: Phase II
Conditions: Triple Negative Metastatic Breast Cancer
Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Drug: Capecitabine
Phase: Phase II
Recruiting
Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Bevacizumab, Drug: Paclitaxel
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Bevacizumab, Drug: Paclitaxel
Phase: Phase II
Recruiting
RAD001 Plus Carboplatin in Breast Cancer Patients
Conditions: Breast Cancer
Interventions: Drug: RAD001
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: RAD001
Phase: Phase II
Recruiting
A Study of Avastin (Bevacizumab) Added to Herceptin (Trastuzumab) Plus Docetaxel in the Neoadjuvant Setting in Patients With Early Stage HER2-Positive Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: trastuzumab [Herceptin], Drug: docetaxel
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: trastuzumab [Herceptin], Drug: docetaxel
Phase: Phase II
Recruiting
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
Conditions: Recurrent Breast Cancer
Interventions: Drug: Foretinib
Phase: Phase II
Conditions: Recurrent Breast Cancer
Interventions: Drug: Foretinib
Phase: Phase II
Recruiting
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
Conditions: Breast Cancer
Interventions: Drug: fulvestrant, Drug: selumetinib
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: fulvestrant, Drug: selumetinib
Phase: Phase II
Recruiting
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
Conditions: Metastatic Breast Cancer
Interventions: Drug: Apatinib
Phase: Phase II
Conditions: Metastatic Breast Cancer
Interventions: Drug: Apatinib
Phase: Phase II
Recruiting
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: bevacizumab, Drug: MetMAb, Drug: paclitaxel, Drug: placebo
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: bevacizumab, Drug: MetMAb, Drug: paclitaxel, Drug: placebo
Phase: Phase II
Recruiting
Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: bevacizumab, Drug: no bevacizumab
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: bevacizumab, Drug: no bevacizumab
Phase: Phase II
Recruiting
Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Sorafenib
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Sorafenib
Phase: Phase II
Recruiting
A Study of Avastin (Bevacizumab) in Combination With Gemcitabine and Carboplatin as First Line Treatment in Patients With Triple Negative Metastatic Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: gemcitabine, Drug: carboplatin
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: bevacizumab [Avastin], Drug: gemcitabine, Drug: carboplatin
Phase: Phase II
Recruiting
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Conditions: Postmenopausal Women,, Locally Advanced or Metastatic Breast Cancer
Interventions: Drug: Everolimus + Letrozole
Phase: Phase II
Conditions: Postmenopausal Women,, Locally Advanced or Metastatic Breast Cancer
Interventions: Drug: Everolimus + Letrozole
Phase: Phase II
Recruiting
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Conditions: Breast Cancer
Interventions: Biological: Ramucirumab DP, Biological: IMC-18F1, Drug: Capecitabine
Phase: Phase II
Conditions: Breast Cancer
Interventions: Biological: Ramucirumab DP, Biological: IMC-18F1, Drug: Capecitabine
Phase: Phase II
Recruiting
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM2)
Conditions: Breast Cancer
Interventions: Drug: ridaforolimus + dalotuzumab, Drug: exemestane, Drug: ridaforolimus, Drug: dalotuzumab
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: ridaforolimus + dalotuzumab, Drug: exemestane, Drug: ridaforolimus, Drug: dalotuzumab
Phase: Phase II
Recruiting
TKI258 for Metastatic Inflammatory Breast Cancer Patients
Conditions: Breast Cancer
Interventions: Drug: Dovitinib
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Dovitinib
Phase: Phase II
Recruiting
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Conditions: Breast Neoplasms, Breast Cancer, Cancer of the Breast
Interventions: Drug: Lapatinib and Everolimus
Phase: Phase II
Conditions: Breast Neoplasms, Breast Cancer, Cancer of the Breast
Interventions: Drug: Lapatinib and Everolimus
Phase: Phase II
Recruiting
Akt Inhibitor MK-2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation and/or PTEN Loss
Conditions: Breast Cancer
Interventions: Drug: MK2206
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: MK2206
Phase: Phase II
Recruiting
Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis
Conditions: Breast Neoplasms, Metastatic Malignant Neoplasm to the Leptomeninges, Metastatic Malignant Neoplasm to Brain
Interventions: Drug: Bevacizumab, etoposide, cisplatin, Drug: Intrathecal methotrexate
Phase: Phase II
Conditions: Breast Neoplasms, Metastatic Malignant Neoplasm to the Leptomeninges, Metastatic Malignant Neoplasm to Brain
Interventions: Drug: Bevacizumab, etoposide, cisplatin, Drug: Intrathecal methotrexate
Phase: Phase II
Recruiting
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer
Interventions: Drug: Lapatinib and RAD-001
Phase: Phase II
Conditions: Metastatic Breast Cancer
Interventions: Drug: Lapatinib and RAD-001
Phase: Phase II
Recruiting
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Conditions: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus, Drug: Vinorelbine, Drug: Trastuzumab
Phase: Phase II
Conditions: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus, Drug: Vinorelbine, Drug: Trastuzumab
Phase: Phase II
Recruiting
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Akt inhibitor MK2206, Genetic: microarray analysis, Genetic: mutation analysis, Genetic: western blotting, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Other: pharmacological study, Procedure: neoadjuvant therapy, Procedure: therapeutic conventional surgery
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Akt inhibitor MK2206, Genetic: microarray analysis, Genetic: mutation analysis, Genetic: western blotting, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Other: pharmacological study, Procedure: neoadjuvant therapy, Procedure: therapeutic conventional surgery
Phase: Phase II
Recruiting
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
Conditions: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel and Sorafenib, Drug: Paclitaxel
Phase: Phase II
Conditions: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel and Sorafenib, Drug: Paclitaxel
Phase: Phase II
Recruiting
Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
Phase: Phase II
Recruiting
Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer
Conditions: Locally Advanced HER2-negative Breast Cancer
Interventions: Drug: Paclitaxel/doxorubicin/cyclophosphamide, Drug: Paclitaxel/doxorubicin/cyclophosphamide
Phase: Phase II
Conditions: Locally Advanced HER2-negative Breast Cancer
Interventions: Drug: Paclitaxel/doxorubicin/cyclophosphamide, Drug: Paclitaxel/doxorubicin/cyclophosphamide
Phase: Phase II
Recruiting
PET-Guided Chemotherapy and Hormone Therapy in Treating Women With Previously Untreated Invasive Breast Cancer
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Biological: trastuzumab, Drug: capecitabine, Drug: cyclophosphamide, Drug: docetaxel, Drug: epirubicin hydrochloride, Drug: vinorelbine tartrate, Genetic: gene expression analysis, Genetic: microarray analysis, Procedure: neoadjuvant therapy, Procedure: positron emission tomography, Procedure: therapeutic conventional surgery
Phase: Phase II
Conditions: Breast Cancer
Interventions: Biological: bevacizumab, Biological: trastuzumab, Drug: capecitabine, Drug: cyclophosphamide, Drug: docetaxel, Drug: epirubicin hydrochloride, Drug: vinorelbine tartrate, Genetic: gene expression analysis, Genetic: microarray analysis, Procedure: neoadjuvant therapy, Procedure: positron emission tomography, Procedure: therapeutic conventional surgery
Phase: Phase II
Recruiting
Pazopanib Hydrochloride and Anastrozole Before Surgery in Treating Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions: Drug: anastrozole, Drug: pazopanib hydrochloride, Procedure: therapeutic conventional surgery
Phase: Phase II
Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions: Drug: anastrozole, Drug: pazopanib hydrochloride, Procedure: therapeutic conventional surgery
Phase: Phase II
Recruiting
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Conditions: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B), Drug: Eribulin
Phase: Phase II
Conditions: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B), Drug: Eribulin
Phase: Phase II
Recruiting
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Cabozantinib
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Cabozantinib
Phase: Phase II
Recruiting
Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: metroCX
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: metroCX
Phase: Phase II
Recruiting
Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: EndoTAG-1
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: EndoTAG-1
Phase: Phase II
Not yet recruiting
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Conditions: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel, Drug: Trastuzumab, Docetaxel, Bevacizumab, Drug: Trastuzumab+Docetaxel+NPLD, Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab
Phase: Phase II
Conditions: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel, Drug: Trastuzumab, Docetaxel, Bevacizumab, Drug: Trastuzumab+Docetaxel+NPLD, Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab
Phase: Phase II
Not yet recruiting
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
Conditions: Breast Cancer, Breast Neoplasm
Interventions: Drug: Pazopanib
Phase: Phase II
Conditions: Breast Cancer, Breast Neoplasm
Interventions: Drug: Pazopanib
Phase: Phase II
Not yet recruiting
Study of How Well Letrozole Works in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer
Conditions: Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
Interventions: Drug: letrozole, Drug: lapatinib, Drug: everolimus
Phase: Phase II
Conditions: Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
Interventions: Drug: letrozole, Drug: lapatinib, Drug: everolimus
Phase: Phase II
Not yet recruiting
BKM120 in Cancers With PIK3CA Activating Mutations
Conditions: Lung Cancer, Breast Cancer, Colorectal Cancer, Cholangiocarcinoma, Solid Tumors
Interventions: Drug: BKM120
Phase: Phase II
Conditions: Lung Cancer, Breast Cancer, Colorectal Cancer, Cholangiocarcinoma, Solid Tumors
Interventions: Drug: BKM120
Phase: Phase II
Not yet recruiting
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
Conditions: Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer
Interventions: Drug: Vinorebine, Everolimus, Drug: Vinorelbine
Phase: Phase II
Conditions: Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer
Interventions: Drug: Vinorebine, Everolimus, Drug: Vinorelbine
Phase: Phase II
Not yet recruiting
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Conditions: Metastatic Breast Cancer
Interventions: Drug: Dovitinib, Drug: Fulvestrant
Phase: Phase II
Conditions: Metastatic Breast Cancer
Interventions: Drug: Dovitinib, Drug: Fulvestrant
Phase: Phase II
Clinical Trial Data provided by http://www.clinicaltrials.gov.